SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Pfizer - Quaterly Results

03 Nov 2021 Evaluate
The company witnessed a 6.86% growth in the revenue at Rs. 6362.60 millions for the quarter ended September 2021 as compared to Rs. 5954.10 millions during the year-ago period.A humble growth in net profit of 8.81% reported in the quarter ended September 2021 to Rs. 1429.50  millions from Rs. 1313.70 millions.The Operating Profit of the company witnessed a decrease to 2044.00 millions from 2154.70 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 6362.60 5954.10 6.86 13854.30 11103.00 24.78 22385.50 21516.50 4.04
Other Income 150.30 121.50 23.70 272.70 293.50 -7.09 811.20 1840.20 -55.92
PBIDT 2044.00 2154.70 -5.14 5023.80 4189.60 19.91 7932.40 7565.80 4.85
Interest 22.10 47.10 -53.08 44.60 77.20 -42.23 151.10 108.50 39.26
PBDT 2021.90 2107.60 -4.07 4979.20 4112.40 21.08 7781.30 7457.30 4.34
Depreciation 272.30 277.30 -1.80 542.30 548.70 -1.17 1094.10 1032.40 5.98
PBT 1749.60 1830.30 -4.41 4436.90 3563.70 24.50 6687.20 6424.90 4.08
TAX 320.10 516.60 -38.04 1008.30 1005.50 0.28 1711.10 1333.60 28.31
Deferred Tax -97.50 -49.50 96.97 -117.20 -61.00 92.13 -125.20 1.60 -7925.00
PAT 1429.50 1313.70 8.81 3428.60 2558.20 34.02 4976.10 5091.30 -2.26
Equity 457.50 457.50 0.00 457.50 457.50 0.00 457.50 457.50 0.00
PBIDTM(%) 32.13 36.19 -11.23 36.26 37.73 -3.90 35.44 35.16 0.78

Pfizer Share Price

4798.15 -12.90 (-0.27%)
11-May-2026 10:38 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1283.70
Cipla 1335.55
Zydus Lifesciences 938.00
Lupin 2250.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×